Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SARAS SURENDRA SHARMA

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1568841161
CMS profile
1321644
Location
NASHVILLE, TN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$1,738.95

87 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,738.95 87

By paying entity

PY2022 · entire year · sorted by reported total

Page 2 of 2; records 51–87 of 87 matching records. This page contains 37 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SARAS SURENDRA SHARMA

NPI 1568841161 · CMS profile ID 1321644

Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology

NASHVILLE, TN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–87 of 87 matching records. This page contains 37 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1568841161?year=2022&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SARAS SURENDRA SHARMA, NPI 1568841161, CMS profile ID 1321644. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–87 of 87 matching records. This page contains 37 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1568841161?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). SARAS SURENDRA SHARMA, NPI 1568841161, CMS profile ID 1321644. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–87 of 87 matching records. This page contains 37 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1568841161?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
SARAS SURENDRA SHARMA, NPI 1568841161, CMS profile ID 1321644, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–87 of 87 matching records. This page contains 37 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1568841161?year=2022&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

87 matching records · $1,738.95 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 87 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–87 of 87.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ABBVIE INC. $25.5608/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891579875 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $16.8908/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959843997 CMS
ABBVIE INC. $8.5208/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891579873 CMS
Genentech USA, Inc. $17.6908/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950698585 CMS
Janssen Biotech, Inc. $12.5008/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886560283 CMS
ABBVIE INC. $25.5908/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891579871 CMS
INTERCEPT PHARMACEUTICALS, INC. $26.8808/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 951535511 CMS
Janssen Biotech, Inc. $0.5008/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886560277 CMS
Gilead Sciences, Inc. $17.5207/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929615595 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $20.8007/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959891041 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $18.6607/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959975543 CMS
Gilead Sciences, Inc. $20.4907/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929615599 CMS
ABBVIE INC. $17.1507/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891579865 CMS
ABBVIE INC. $2.1207/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891579867 CMS
ABBVIE INC. $11.5507/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891579869 CMS
Janssen Biotech, Inc. $19.0007/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886560235 CMS
ABBVIE INC. $29.6107/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891579861 CMS
ABBVIE INC. $17.7407/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891579863 CMS
Merck Sharp & Dohme LLC $15.3107/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944183589 CMS
Janssen Biotech, Inc. $14.9907/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886560287 CMS
Ironwood Pharmaceuticals, Inc $17.2707/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 957929315 CMS
Janssen Biotech, Inc. $17.3906/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886560229 CMS
Gilead Sciences, Inc. $27.1806/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929615611 CMS
Merck Sharp & Dohme LLC $20.4206/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944185313 CMS
Merck Sharp & Dohme LLC $19.0906/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944199969 CMS
ABBVIE INC. $20.5706/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891579859 CMS
Janssen Biotech, Inc. $14.9906/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886560271 CMS
RedHill Biopharma Inc. $21.3906/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 902953113 CMS
Janssen Biotech, Inc. $24.3306/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886560212 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $20.0005/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959605189 CMS
Gilead Sciences, Inc. $17.5205/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929615593 CMS
Gilead Sciences, Inc. $31.0405/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929615613 CMS
Merck Sharp & Dohme LLC $17.5005/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944293215 CMS
Janssen Biotech, Inc. $10.6905/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886560205 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $19.7305/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959521057 CMS
Gilead Sciences, Inc. $26.2004/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929615609 CMS
ABBVIE INC. $20.5401/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891579857 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $228.94 2
PY2022 $1,738.95 87
PY2023 $3,266.49 122
PY2024 $1,927.65 97
PY2025 $1,937.34 100

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $483,654.88 23
PY2024 Recipient $3,868.00 2
PY2024 Principal investigator $374,657.56 12
PY2023 Principal investigator $2,461.31 2

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

23 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Madrigal Pharmaceuticals $2,109.46 12/19/2025 Non-covered Recipient Entity
QUALITY MEDICAL RESEARCH PLLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248254367
Principal investigator 1 Madrigal Pharmaceuticals $2,109.46 12/04/2025 Non-covered Recipient Entity
QUALITY MEDICAL RESEARCH PLLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248253445
Principal investigator 1 Madrigal Pharmaceuticals $2,109.46 11/25/2025 Non-covered Recipient Entity
QUALITY MEDICAL RESEARCH PLLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248252928
Principal investigator 1 Madrigal Pharmaceuticals $2,660.93 09/23/2025 Non-covered Recipient Entity
QUALITY MEDICAL RESEARCH PLLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248250604
Principal investigator 1 Madrigal Pharmaceuticals $2,660.93 09/12/2025 Non-covered Recipient Entity
QUALITY MEDICAL RESEARCH PLLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248249944
Principal investigator 1 Madrigal Pharmaceuticals $2,660.93 08/21/2025 Non-covered Recipient Entity
QUALITY MEDICAL RESEARCH PLLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248248925
Principal investigator 1 Madrigal Pharmaceuticals $2,410.84 07/04/2025 Non-covered Recipient Entity
QUALITY MEDICAL RESEARCH PLLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248246533
Principal investigator 1 Madrigal Pharmaceuticals $2,410.84 06/12/2025 Non-covered Recipient Entity
QUALITY MEDICAL RESEARCH PLLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248245274
Principal investigator 1 Madrigal Pharmaceuticals $2,410.84 06/05/2025 Non-covered Recipient Entity
QUALITY MEDICAL RESEARCH PLLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248244891
Principal investigator 1 Madrigal Pharmaceuticals $2,660.93 05/15/2025 Non-covered Recipient Entity
QUALITY MEDICAL RESEARCH PLLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248243652
Principal investigator 1 Madrigal Pharmaceuticals $9,957.85 03/06/2025 Non-covered Recipient Entity
QUALITY MEDICAL RESEARCH PLLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248240519
Principal investigator 1 Madrigal Pharmaceuticals $8,424.99 02/06/2025 Non-covered Recipient Entity
QUALITY MEDICAL RESEARCH PLLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248239332
Principal investigator 1 Eli Lilly and Company $4,432.90 01/31/2025 Non-covered Recipient Entity
ASCENSION MEDICAL GROUP
A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3549492 ONCE DAILY COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1187875525
Principal investigator 1 Eli Lilly and Company $1,089.09 01/21/2025 Non-covered Recipient Entity
ASCENSION MEDICAL GROUP
A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR CHRONIC WEIGHT MANAGEMENT IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1187875317
Principal investigator 1 Eli Lilly and Company $54,493.00 01/21/2025 Non-covered Recipient Entity
ASCENSION MEDICAL GROUP
PHASE 2 STUDY WITH COMBINATION OF VEMURAFENIB WITH COBIMETINIB IN B-RAF V600E/K MUTATED MELANOMA PATIENTS TO NORMALIZE LDH AND OPTIMIZE NIVOLUMAB AND IPILIMUMAB THERAPY No dispute reported 06/30/2026 1187875319
Principal investigator 1 Eli Lilly and Company $22,289.00 01/21/2025 Non-covered Recipient Entity
ASCENSION MEDICAL GROUP
A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1187876375
Principal investigator 1 Eli Lilly and Company $55,966.00 01/21/2025 Non-covered Recipient Entity
ASCENSION MEDICAL GROUP
A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR CHRONIC WEIGHT MANAGEMENT IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1187876827
Principal investigator 1 Eli Lilly and Company $198,681.00 01/21/2025 Non-covered Recipient Entity
ASCENSION MEDICAL GROUP
A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 AND TIRZEPATIDE, ALONE OR IN COMBINATION, IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH TYPE 2 DIABETES No dispute reported 06/30/2026 1187877111
Principal investigator 1 Eli Lilly and Company $89,911.00 01/21/2025 Non-covered Recipient Entity
ASCENSION MEDICAL GROUP
A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3549492 ONCE DAILY COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1187880863
Principal investigator 1 Eli Lilly and Company $1,391.18 01/20/2025 Non-covered Recipient Entity
ASCENSION MEDICAL GROUP
A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR CHRONIC WEIGHT MANAGEMENT IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1187875321
Principal investigator 1 Eli Lilly and Company $3,257.62 01/09/2025 Non-covered Recipient Entity
ASCENSION MEDICAL GROUP
PHASE 2 STUDY WITH COMBINATION OF VEMURAFENIB WITH COBIMETINIB IN B-RAF V600E/K MUTATED MELANOMA PATIENTS TO NORMALIZE LDH AND OPTIMIZE NIVOLUMAB AND IPILIMUMAB THERAPY No dispute reported 06/30/2026 1187875523
Principal investigator 1 Eli Lilly and Company $667.52 01/09/2025 Non-covered Recipient Entity
ASCENSION MEDICAL GROUP
A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1187877755
Principal investigator 1 Eli Lilly and Company $8,889.11 01/09/2025 Non-covered Recipient Entity
ASCENSION MEDICAL GROUP
A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 AND TIRZEPATIDE, ALONE OR IN COMBINATION, IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH TYPE 2 DIABETES No dispute reported 06/30/2026 1187880861